Rothwell Figg

It is fairly standard language in privacy policies: “This privacy policy may be amended or updated from time to time, so please check back regularly for updates.”  It sends the message that the company can change its data practices and policies without ever notifying the end-user. It tells the end-user that the burden is on them

BASE Air is a company at the leading edge of safety in the heavy vehicle industry. Founded in 2005 by Matthew Vaughan in Australia, the company focuses on Balance and Safety Enhancement (BASE) for heavy-duty vehicle stability. BASE Air’s technology is a pressure-control system capable of integrating into a vehicle’s existing air suspension, or available

In a long-awaited milestone in the gene therapy space, the Food and Drug Administration (FDA) approved two gene therapies to cure sickle cell disease (SCD).  Soon thereafter these approvals, a key licensing agreement was announced between Vertex and Editas for Cas9 gene editing technology.

Gene therapy is a new type of treatment with the potential

Gene therapy is part of a new wave of medicine that approaches disease treatment by addressing the root causes rather than focusing on treating or reducing symptoms. Currently, gene therapies are being developed for treatment of inherited diseases, autoimmune diseases, cancer, and infectious diseases. In July 2023, we posted about a series of FDA approvals

On Oct. 30, President Joe Biden issued an executive order on safe, secure and trustworthy artificial intelligence.[1]

The executive order provides a sprawling list of directives aimed at establishing standards for AI safety and security and protecting privacy.

While the executive order acknowledges the executive branch’s lack of authority for any lawmaking or rulemaking, AI

The Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act was introduced on June 22, 2023, with the aim to reform the U.S. Patent Trial and Appeal Board (PTAB).  The PREVAIL Act serves as a supplement to the proposed STRONGER Patents Act, introduced in 2019.

The drafters have identified three key goals of the

Following its many warnings of impending enforcement action against entities providing Artificial Intelligence (“AI”) products, the FTC has officially launched an investigation into OpenAI[1]. The FTC initiates its investigation on the heels of the Center for AI and Digital Policy’s July 10, 2023 supplement to its March 30, 2023 complaint, which requests that

After decades of intense scientific research into developing gene editing technologies, and more than a few setbacks, the field has produced a number of success stories in recent years, demonstrating that regulatory agencies are increasingly likely to accept safety, efficacy, and durability data to approve such therapies. These advances have culminated in a series of FDA